Medtronic plc (MDT) Equity Report Q4FY24
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
Â
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Â
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
 MDT’s revenue climbed by 1% to $8.58bn in Q4FY24 from $8.54bn in Q4FY23 and COGS as a % of sales decreased to 34% in Q4FY24 from 35% in Q4FY23. On a yearly basis, it stood at around 34% in FY24 and FY23.
Over the past 3 months, Medtronic stock price stood around the same level at $81.51 against the three-month back price of 81.76.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
